Remove 2009 Remove Doctors Remove Healthcare Provider
article thumbnail

Biogen’s $900 million settlement signals scrutiny on speaker fees

Pharmaceutical Technology

In 2009, former Biogen employee Michael Bawduniak filed a lawsuit claiming that Biogen had violated the False Claims Act and the Anti-Kickback Statute by providing millions of dollars to healthcare providers (HCPs) as an incentive to prescribe three of its multiple sclerosis (MS) drugs.

article thumbnail

What are the Benefits of Patient Portals?

Referral MD

Since the inception of electronic health records (EHR) in 2009, the American medical practice has been transitioning to the cloud. One of the latest iterations of our digitization comes in the form of the patient portal, an online hub designed to keep healthcare consumers in the treatment loop. For Providers. Better bottom line.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Unleashing the power of healthcare analytics data to improve patient loyalty and referrals

Clarify Health

Most healthcare providers’ priorities include retaining patients and improving referral patterns to increase revenue. It also shows that doctors are unlikely to change their referral patterns unless they are actively engaged by a physician liaison team member.

article thumbnail

Race to the finish: pharma edges closer to approval with RSV vaccines

Pharmaceutical Technology

During the 2009–19 period, children in the US ages five years and younger accounted for 58, 000 annual RSV-related hospitalisations and 100–500 annual deaths. This would be preferable for patients as doctors must administer Synagis to patients five times per month during peak RSV season.

Pharma 64
article thumbnail

Exforge antitrust settlement caps Novartis’ year of legal disputes

Pharmaceutical Technology

District Judge Kimba Wood dismissed a whistleblower lawsuit against Novartis, that claimed the company had bribed doctors with kickbacks at speaker programs to incentivise doctors to prescribe Gilenya. This is the second time that allegations of Novartis violating the False Claims Act have been dismissed in the last three years.